Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
GEN - Genetic Engineering and Biotechnology News3d
BMS to Acquire Abecma Partner 2seventy bio for $286M
The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.
Medpage Today on MSN10mon
Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management
A second key mutation in myelofibrosis, the myeloproliferative leukemia proto-oncogene (MPL ... E.R. Squibb & Sons, Celgene, ...
pharmaphorum6d
Celgene bags FDA okay for Revlimid combo in lymphoma
Celgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use alongside Roche’s Rituxan for two additional forms of indolent non-Hodgkin’s ...
Nature5y
Celgene buys Signal
Celgene (Warren, NJ), a developer of chirally pure drugs, agreed on June 30 to purchase gene-regulation firm Signal Pharmaceuticals (San Diego, CA) for $200 million in an all-stock deal.
Nature6y
Celgene acquires Gloucester Pharmaceuticals, gaining approved HDAC inhibitor
Celgene has acquired Gloucester Pharmaceuticals for US$340 million upfront and up to $300 million in milestones. Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone ...
pharmaphorum5y
AI drug R&D company Exscientia signs deal with Celgene
UK artificial intelligence (AI) drug discovery company Exscientia has agreed a three year drug discovery deal with Celgene, focusing on finding new cancer and autoimmune drugs. Celgene will pay $ ...